Chen 2006.

Methods	Inclusion: Eligible participants had to meet following criteria: cytological or histological diagnosis of stage IIIb with malignant effusion, or stage IV NSCLC; 70 years or older; no prior chemotherapy or immunotherapy; PS of 0 to 2 on the WHO scale; bi‐dimensionally measurable disease; adequate bone marrow reserve. Exclusion: Patients were ineligible if they had: signs or symptoms of brain metastases; inadequate liver function (serum bilirubin > 1.5 times and alanine aminotransferase/aspartate transaminase > 3 times upper limit of normal); inadequate renal function (serum creatinine > 1.5 times upper limit of normal).
Participants	Arm I: 40 people Arm II: 41 people
Interventions	Arm I: paclitaxel (160 mg/m2) iv over 3 hours on day 1 and carboplatin (AUC 6 mg/mL X minutes) iv over 1 hour on day 1, every 3 weeks Arm II: paclitaxel (160 mg/m2) iv over 3 hours on day 1 and cisplatin (60 mg/m2) iv over 1 hour on day 1, every 3 weeks
Outcomes	Primary outcome: response rate Secondary outcomes: time to progression; toxicity; overall survival
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Participants were stratified according staging and PS.
Allocation concealment (selection bias)	Low risk	Participants were randomised into the paclitaxel plus carboplatin or paclitaxel plus cisplatin treatment arm by an outside centre not involved in the study.
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	No information about blinding process
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	No information about blinding process
Incomplete outcome data (attrition bias) All outcomes	Low risk	No evidence of incomplete outcome
Selective reporting (reporting bias)	Low risk	No evidence of selective reporting bias
Other bias	High risk	Phase II trial and a study of elderly people, so could be associated with higher response rate